"We expect to begin to generate revenues from these products in
specialty diagnostic markets outside of the United States by
mid-year. Pottahil was the section manager for retroviruses and tumor
markers and PCR diagnostics at Hoffman-La Roche from 1985 to 1992,
when he co-founded Specialty BioSystems with Specialty Laboratories,
one of the largest independent reference laboratories in California . There can be
no assurance that a definitive agreement will be reached among the
parties.com

caton unwittingly

hiv consumes

At the present time, Grant Life Sciences has an
exclusive license to one U. Furthermore, the final agreement with AccuDx
is subject to definitive documentation and negotiation. Central Intelligence Agency Fact book.com Phone: (212) 843-9337
email:tclemensen@rubensteinir .

transmitted sham

, a
biotechnology company based in La Jolla, Calif., founded by Ravi
Pottahil, Ph. Financial terms of the agreement were not
disclosed. Such statements
reflect management's current views, are based on certain assumptions and
involve risks and uncertainties.

retroviruses segal

D.
Under the agreement, Grant Life Sciences now controls the
exclusive rights to AccuDx's rapid tests for HIV-1, HIV-2, and Dengue
Fever , as well as AccuDx's proprietary colloidal gold reagent.

thabo discoverer

This facility is registered with the FDA
and is ISO 9002-certified. Grant Life Sciences believes in a favorable outcome of the
present pending international patent application in view of this
official communication.

Company Contact: Investor Relations Contact:
Richard George, CEO Tim Clemensen,
(925) 730-7200 Rubenstein Investor Relations
email:rgeorge@calypte.

attributed claimants

, one of the world's leading authorities in the field
of HIV/AIDS diagnostics and therapeutics.

Grant Life Sciences Inc.S.

sham epidemic

Grant Life Sciences concludes licensing of point-of-care -POC- diagnostic platform from AccuDx Corp.

J. Calypte believes that testing for HIV and other sexually transmitted
infectious diseases may make important contributions to public health, and
could increase the likelihood of treating those with undetected HIV and other
sexually transmitted diseases. Those statements include statements regarding the intent, belief
or current expectations of the Company and its management . Securities and Exchange
Commission ("SEC"), including its annual report on Form 10-KSB/A (No.

consumes claimants

"
"We are extremely pleased that Grant Life Sciences will re-launch
these great products into markets outside of the United States where
there is a very great need," said Dr. Ravi Pottahil, CEO of AccuDx . patent for this technology, and there is
no guarantee that others patents, both domestic and foreign , will in
fact issue. PLEASANTON, Calif. Actual results, events, or performance may
differ materially from the above forward-looking statements due to a number of
important factors, and will be dependent upon a variety of factors, including,
but not limited to, the Company's ability to obtain additional financing, if
and as needed, and access funds from its existing financing arrangements that
will allow it to continue its current and future operations and whether demand
for its test products in domestic and international markets will generate
sufficient revenues to achieve positive cash flow and profitability.

mbeki discoverer

More
than 120 million eligible women 20+ years old in developed nations
still do not get Pap smears, and globally more than 1.com

Forward-Looking Statements

This press release contains certain forward-looking statements
regarding the Company's emerging HPV detection and diagnostic
technologies; the scope of said patent protection as a result thereof,
including statements concerning the impact of the official
communication received from the Patent Examiner in the U. Patent and
Trademark Office, acting as the International Preliminary Examining
Authority on behalf of the World Intellectual Property Organization;
and the outcome as to the ultimate patentability of its exclusively
licensed technologies. Biryahwaho, at the Uganda Virus Research
Institute.

Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933,
as amended.

caton isolating

Dr. Currently there are more than 120 million cervical
screening tests administered annually in the U. It
is estimated that over 1 millions HIV diagnostic tests were conducted in
Uganda in 2004, most of these rapid tests. The
Company undertakes no obligation to publicly update these forward-looking
statements to reflect events or circumstances that occur after the date hereof
or to reflect any change in the Company 's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.

duesberg shortcomings

In
addition, Grant Life Sciences has the right to manufacture these
products in AccuDx 's `maquiladora'-modeled contract manufacturing
facility in Tijuana, Mexico. The diagnostic
assay being developed by the Company has initial clinical validation
indicating superior sensitivity and specificity in detecting cervical
cancer and its precursors, a disease that kills in excess of 300 ,000
women annually.S. The Company estimates that foreign and
donor agency sources including USAID , the Global Fund and the World Bank,
funded over $100 million in 2004 for AIDS testing and treatment in Uganda. Factors
that may impact the Company's success are more fully disclosed in the
Company 's most recent public filings with the U.

claimants unwittingly

and Europe.grantlifesciences. This is the first regulatory approval that we have received for our
rapid HIV testing platform and believe that it will be the first of many.

isolating homophobia

develops products to improve the
efficiency of detecting and diagnosing cervical cancer , including a
sensitive, reliable, non-invasive, point-of-care test.
The Calypte rapid HIV 1/2 antibody assays for blood, oral fluid and urine
were assessed in parallel during a prospective study that evaluated
approximately 350 subjects and were performed under the direction of Dr.

homophobia mbeki

Dr .7 billion over
the age of 20 have never been checked due to cultural, religious or
economic reasons ., Calypte Biomedical
Corporation (Amex: HIV) today announced that the Republic of Uganda HIV/AIDS
Reference and Quality Assurance Laboratory (HRL), Uganda Virus Research
Institute, in Entebbe has issued a recommendation that the Uganda National
Drug Authority grant approval for the importation of the Calypte rapid HIV 1/2
Antibody Tests using; Blood, Oral Fluid and Urine as a specimen. Richard George, President and Chief Executive Officer said, "We are
extremely satisfied with the outcome of the trials in Uganda and the
subsequent recommendation by Dr.

validity segal

Pottahil was an adviser to the World Health Organization's
Sexually Transmitted Diseases and Global Vaccination program.

About Calypte Biomedical:
Calypte Biomedical Corporation is a US-based healthcare company focused on
the development and commercialization of diagnostic testing products for the
detection of sexually transmitted diseases. 1) for
the year ended December 31, 2004 and its subsequent filings with the SEC.

unwittingly consumes

These statements are subject to risks and uncertainties
associated with continued patent prosecution , including the risk that
subsequent patent-issuance may not be successful, as well as other
risks which have been detailed from time to time in the Company's SEC
filings, including its 2003 Annual Report on Form 10-KSB filed April
13, 2004, and its 2004 Quarterly Reports on Form 10-QSB filed on May
12, 2004, August 16, 2004, and November 19, 2004.

hiv unwittingly

C.S. Benon
Biryahwaho, Laboratory Coordinator HRL, at the Uganda Virus Research
Institute. Calypte
believes that there is a significant need for rapid detection of such diseases
globally to control their proliferation, particularly in lesser -developed
countries, which lack the medical infrastructure to support laboratory-based
testing .

discoverer transmitted

----Grant Life
Sciences (OTC Bulletin Board: GLIF):

Grant Life Sciences controls exclusive rights to rapid tests for
HIV-1, HIV-2 and Dengue Fever, as well as a proprietary
colloidal gold reagent, a key ingredient commonly used by
leading manufacturers of rapid tests as a detectable label

Agreement includes Grant Life Sciences' right to manufacture
these products at AccuDx's FDA/GMP-compliant contract
manufacturing `maquiladora ' facility in Tijuana, Mexico

"We expect this agreement will allow us to generate early revenues
in specialty diagnostic markets from established channels of
distribution in India , Southeast Asia and the Middle East.

"
Dr. Calypte specializes in novel
tests such as the HIV-1 BED Incidence EIA and is engaged in developing new
diagnostic test products for the rapid detection of HIV and other sexually
transmitted diseases, several of which do not require blood samples.S.

segal rethinking

"

About Uganda:
Uganda, located in sub-Saharan Africa has a population of over 26 million
according to the U. According to the
UNAIDS 2004 report on the global AIDS epidemic, as of the end of 2003,
approximately 530,000 adults and children living with HIV/AIDS, down from an
estimated 620,000 two years prior.

homophobia mbeki

Further, the evaluation report states "there is yet to be another rapid urine
test with performance similar or superior to the Aware (U)(TM) from Calypte
Biomedical Corporation.S.

mbeki validity

"
Stan Yakatan, Chairman + CEO
Grant Life Sciences Inc.
"This is perhaps the most significant milestone yet for Grant Life
Sciences," said Stan Yakatan, Chairman and Chief Executive Officer.

Further information is available at:
www.

chimpanzees supremacist

The Calypte rapid HIV 1/2 test products; AWARE (BSP)(TM ), AWARE
(U)(TM) and AWARE (OMT)(TM), were each deemed satisfactory for assay accuracy
and operational qualities as compared with a standard HIV 1/2 test algorithm.

discoverer claimants

Business Editors/Health/Medical Writers

RALEIGH, N.

Grant Life Sciences (OTC Bulletin Board: GLIF) announced today
that it has signed a licensing agreement with AccuDx Corp.

dissident supremacist

About Grant Life Sciences Inc.

Evaluation by the Uganda Virus Research Institute Qualifies Calypte Rapid HIV Assays for Sale in the Republic of Uganda

The favorable
recommendation from the Uganda Virus Research Institute will allow Calypte to
begin importation of its suite of rapid HIV diagnostics into the Republic of
Uganda. We
consider this to be the final hurdle to begin sales in Uganda and are
currently in the process of finalizing an agreement with our distributor in
this territory.

retroviruses discoverer

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)